<DOC>
	<DOC>NCT01557348</DOC>
	<brief_summary>This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single previous TNF-inhibitor. Data will be collected from each patient from the time of change in biologic therapy for 12 months.</brief_summary>
	<brief_title>An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients with rheumatoid arthritis (RA) who have not responded or have been intolerant to a single TNFinhibitor therapy Initiated on treatment with MabThera/Rituxan or an alternative TNFinhibitor therapy, in accordance with the relevant Summary of Product Characteristics Patients whose second biologic therapy is given as part of a clinical trial studying RA treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>